View Item 

Show simple item record

Healthcare resource utilization among haemophilia A patients in the United States

dc.contributor.authorValentino, L. A.en_US
dc.contributor.authorPipe, S. W.en_US
dc.contributor.authorTarantino, M. D.en_US
dc.contributor.authorYe, X.en_US
dc.contributor.authorXiong, Y.en_US
dc.contributor.authorLuo, M. P.en_US
dc.date.accessioned2012-05-21T15:49:31Z
dc.date.available2013-07-01T14:33:06Zen_US
dc.date.issued2012-05en_US
dc.identifier.citationValentino, L. A. ; Pipe, S. W. ; Tarantino, M. D. ; Ye, X. ; Xiong, Y. ; Luo, M. P. (2012). "Healthcare resource utilization among haemophilia A patients in the United States." Haemophilia 18(3). <http://hdl.handle.net/2027.42/91210>en_US
dc.identifier.issn1351-8216en_US
dc.identifier.issn1365-2516en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/91210
dc.publisherWiley Periodicals, Inc.en_US
dc.publisherBlackwell Publishing Ltden_US
dc.subject.otherSurgeryen_US
dc.subject.otherInhibitorsen_US
dc.subject.otherHaemophiliaen_US
dc.subject.otherEconomicsen_US
dc.subject.otherCosten_US
dc.titleHealthcare resource utilization among haemophilia A patients in the United Statesen_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelOncology and Hematologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumDepartment of Pediatrics and Pathology, University of Michigan, Ann Arbor, MIen_US
dc.contributor.affiliationotherMedical Outcomes Research and Economics, Baxter Bioscience, Westlake Village, CA, USAen_US
dc.contributor.affiliationotherMedical Outcomes Research and Economics, Baxter Bioscience, Deerfield, ILen_US
dc.contributor.affiliationotherBleeding and Clotting Disorders Institute, Peoria, ILen_US
dc.contributor.affiliationotherDepartments of Pediatrics and Internal Medicine, Rush Hemoplilia and Thrombophilia Center, Rush University Medical Center, Chicago, ILen_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/91210/1/j.1365-2516.2011.02677.x.pdf
dc.identifier.doi10.1111/j.1365-2516.2011.02677.xen_US
dc.identifier.sourceHaemophiliaen_US
dc.identifier.citedreferenceHo AY, Height SE, Smith MP. Immune tolerance therapy for haemophilia. Drugs 2000; 60: 547 – 54.en_US
dc.identifier.citedreferenceColowick AB, Bohn RL, Avorn J, Ewenstein BM. Immune tolerance induction in hemophilia patients with inhibitors: costly can be cheaper. Blood 2000; 96: 1698 – 702.en_US
dc.identifier.citedreferenceBlanchette VS, McCready M, Achonu C, Abdolell M, Rivard G, Manco‐Johnson MJ. A survey of factor prophylaxis in boys with haemophilia followed in North American haemophilia treatment centres. Haemophilia 2003; 9 ( Suppl 1 ): 19 – 26.en_US
dc.identifier.citedreferenceSrivastava A, Giangrande PL, Poon MC, Chua M, McGraw A, Wiedel J. Guidelines for the management of hemophilia. Montreal, QC: World Federation of Hemophilia, 2005.en_US
dc.identifier.citedreferenceBerntorp E, Boulyjenkov V, Brettler D et al. Modern treatment of haemophilia. Bull World Health Organ 1995; 73: 691 – 701.en_US
dc.identifier.citedreferenceMedical and Scientific Advisory Council. MASAC document #179. Recommendation Concerning Prophylaxis (Regular administration of clotting factor concentrate to prevent bleeding). 2007. Available at http://www.hemophilia.org/NHFWeb/MainPgs/MainNHF.aspx?menuid=57&contentid=1007. Accessed July 28, 2011.en_US
dc.identifier.citedreferenceGeraghty S, Dunkley T, Harrington C, Lindvall K, Maahs J, Sek J. Practice patterns in haemophilia A therapy – global progress towards optimal care. Haemophilia 2006; 12: 75 – 81.en_US
dc.identifier.citedreferenceManco‐Johnson M, Abshire TC, Shapiro AD et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 2007; 357: 535 – 44.en_US
dc.identifier.citedreferenceMejia‐Carvajal C, Czapek EE, Valentino LA. Life expectancy in hemophilia outcome. J Thromb Haemost 2006; 4: 507 – 9.en_US
dc.identifier.citedreferenceAledort LM, Haschmeyer RH, Pettersson H. A longitudinal study of orthopaedic outcomes for severe factor‐VIII‐deficient haemophiliacs. The Orthopaedic Outcome Study Group. J Intern Med 1994; 236: 391 – 9.en_US
dc.identifier.citedreferencePeerlinck K, Hermans C. Epidemiology of inhibitor formation with recombinant factor VIII replacement therapy. Haemophilia 2006; 12: 579 – 90.en_US
dc.identifier.citedreferenceWight J, Paisley S. The epidemiology of inhibitors in haemophilia A: a systematic review. Haemophilia 2003; 9: 418 – 35.en_US
dc.identifier.citedreferenceKey NS. Inhibitors in congenital coagulation disorders. Br J Haematol 2004; 127: 379 – 91.en_US
dc.identifier.citedreferenceAledort LM. Is the incidence and prevalence of inhibitors greater with recombinant products? Yes. J Thromb Haemost 2004; 2: 861 – 2.en_US
dc.identifier.citedreferenceMorfini M, Haya S, Tagariello G et al. European study on orthopaedic status of haemophilia patients with inhibitors. Haemophilia 2007; 13: 606 – 12.en_US
dc.identifier.citedreferenceMorfini M. Articular status of haemophilia patients with inhibitors. Haemophilia 2008; 14 ( Suppl 6 ): 20 – 2.en_US
dc.identifier.citedreferenceDimichele DM. Management of factor VIII inhibitors. Int J Hematol 2006; 83: 119 – 25.en_US
dc.identifier.citedreferenceMariani G, Kroner B. International immune tolerance registry, 1997 update. Vox Sang 1999; 77 ( Suppl 1 ): 25 – 7.en_US
dc.identifier.citedreferenceLeissinger CA. Prevention of bleeds in hemophilia patients with inhibitors: emerging data and clinical direction. Am J Hematol 2004; 77: 187 – 93.en_US
dc.identifier.citedreferenceClinical Growth Charts. Centers for Disease Control and Prevention. 2000. Available at http://www.cdc.gov/growthcharts/clinical_charts.htm. Accessed December 22, 2010.en_US
dc.identifier.citedreferenceBureau of Labor Statistics. Consumer Price Indexes. Available at http://www.bls.gov/data. Accessed June, 2011.en_US
dc.identifier.citedreferenceEhrenforth S, Kreuz W, Scharrer I et al. Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs. Lancet 1992; 339: 594 – 8.en_US
dc.identifier.citedreferenceDuncan N, Kronenberger W, Roberson C, Shapiro A. VERITAS‐Pro: a new measure of adherence to prophylactic regimens in haemophilia. Haemophilia 2010; 16: 247 – 55.en_US
dc.identifier.citedreferenceChang H, Sher GD, Blanchette VS, Teitel JM. The impact of inhibitors on the cost of clotting factor replacement therapy in haemophilia A in Canada. Haemophilia 1999; 5: 247 – 52.en_US
dc.identifier.citedreferenceUllman M, Hoots WK. Assessing the costs for clinical care of patients with high‐responding factor VIII and IX inhibitors. Haemophilia 2006; 12 ( Suppl 6 ): 74 – 80.en_US
dc.identifier.citedreferenceGautier P, D’Alche‐Gautier MJ, Coatmelec B et al. Cost related to replacement therapy during hospitalization in haemophiliacs with or without inhibitors: experience of six French haemophilia centres. Haemophilia 2002; 8: 674 – 9.en_US
dc.identifier.citedreferenceCoppola A, Di Minno MN, Santagostino E. Optimizing management of immune tolerance induction in patients with severe haemophilia A and inhibitors: towards evidence‐based approaches. Br J Haematol 2010; 150: 515 – 28.en_US
dc.identifier.citedreferenceAstermark J, Morado M, Rocino A et al. Current European practice in immune tolerance induction therapy in patients with haemophilia and inhibitors. Haemophilia 2006; 12: 363 – 71.en_US
dc.identifier.citedreferenceDi Paola J, Aledort L, Britton H et al. Application of current knowledge to the management of bleeding events during immune tolerance induction. Haemophilia 2006; 12: 591 – 7.en_US
dc.identifier.citedreferenceGlobe DR, Cunningham WE, Andersen R et al. The Hemophilia Utilization Group Study (HUGS): determinants of costs of care in persons with haemophilia A. Haemophilia 2003; 9: 325 – 31.en_US
dc.identifier.citedreferenceGlobe DR, Curtis RG, Koerper MA. Utilization of care in haemophilia: a resource‐based method for cost analysis from the Haemophilia Utilization Group Study (HUGS). Haemophilia 2004; 10 ( Suppl 1 ): 63 – 70.en_US
dc.identifier.citedreferenceFischer K, Van den Berg HM, Thomas R et al. Dose and outcome of care in haemophilia – how do we define cost‐effectiveness? Haemophilia 2004; 10 ( Suppl 4 ): 216 – 20.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
j.1365-2516.2011.02677.x.pdf
Size:
416.8KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.